Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy

Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy

Abstract Background Rituximab (RTX) is known to be effective in the treatment of idiopathic membranous nephropathy (IMN), but the specific dosing regimens have not been standardized. The aim of this retrospective study was to assess the clinical efficacy and safety of a B-cell-driven RTX regimen for...

Full description

Saved in:
Bibliographic Details
Main Authors: Kaiqi Guo, Huaxia Zhu, Xingcheng Xu, Lanlan Huang, Huimin Li, Xiaowei Li
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Pharmacology and Toxicology
Subjects:
Rituximab
Membranous nephropathy
B-cell-driven
Immunosuppressant
Online Access:https://doi.org/10.1186/s40360-025-00954-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40360-025-00954-8

Similar Items